Effects of <i>KISS1</i> structural polymorphism on the risk of polycystic ovary syndrome and reproductive hormones in Iraqi women who take metformin.
Kadhem. Ali Hakem AH; Gholizadeh. Ashraf A; Khalaj-Kondori. Mohammad M
Key Findings
- Metformin significantly increased FSH levels in PCOS women (9.39 ± 2.1 vs 5.13 ± 1.53 IU/L).
- Metformin reduced circulating kisspeptin concentrations (395.44 ± 67.83 vs 273.18 ± 42.98 ng/mL).
- A KISS1 G→C SNP was associated with PCOS risk and with a blunted FSH response to metformin (C allele carriers showed lower post‑treatment FSH).
Practical Outcomes
- For self‑experimenters using metformin to manage PCOS, expect an increase in FSH and a drop in kisspeptin levels, which may affect ovulation timing. If you can access genetic testing, a KISS1 G→C variant might predict a weaker hormonal response, suggesting a need to adjust dosage or combine with other interventions. However, the findings are early and specific to a clinical population, so broader application should be cautious.
Summary
In Iraqi women with PCOS, taking metformin raised the hormone FSH and lowered the blood level of kisspeptin. A common genetic change in the KISS1 gene (G→C) was linked to a higher chance of PCOS and to a smaller rise in FSH after metformin. These results hint that both metformin and a person’s KISS1 genetics can influence reproductive hormone balance.
Abstract
To identify the effects of metformin and kisspeptin structural polymorphism on the risk of polycystic ovary syndrome (PCOS) in Iraqi women. Samples were collected at the family planning center of Al-Hassan Teaching Hospital (infertility clinic), Iraq. Hormonal and hematological parameters were measured. Kisspeptin structural polymorphisms were analyzed by polymerase chain reaction using a conventional thermal cycler and Phyre2 predictions. Kisspeptin concentrations were assessed by an enzyme-linked immunosorbent assay. Follicle-stimulating hormone (FSH) was the only sex hormone that changed in women with PCOS after metformin treatment. FSH concentrations were significantly increased after therapy compared with before therapy (9.39 ± 2.1 vs 5.13 ± 1.53 IU/L). We found that a single nucleotide polymorphism substituting G to C was related to PCOS. The kisspeptin structural polymorphism showed that the C allele was related to low FSH concentrations after treatment (6.92 ± 2.2 IU/L to 5.34 ± 1.58 IU/L). Kisspeptin concentrations were significantly lower after metformin treatment than before metformin treatment (395.44 ± 67.83 vs 273.18 ± 42.98 ng/mL). A variation in the <i>KISS1</i> gene or its protein structure may be involved in the development of PCOS. The response to metformin may be used as an indicator and could contribute to the early diagnosis and medical therapy of PCOS.
Study Information
pubmed
2023
2023-09-01T00:00:00.000Z
10.1177/03000605231196837
34